Aetna Cancels Contract With Cerebral Over Controlled Substance Prescribing Issues

The $4.8 billion startup is being investigated by the Department of Justice over its practices around prescribing drugs such as Adderall.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation Venture Capital /venture-capital Editors' Pick editors-pick Source Type: news